Khodayar Ghorban
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Khodayar Ghorban has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
Maryam Dadmanesh
Affiliations Infectious Diseases Research Center, Aja University of Medical Sciences, Tehran, Iran, Department of Infectious Diseases, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran
20 shared publications- Mohammad Mehdi Ranjbar
Department of FMD Razi Vaccine and Serum Research Institute Agricultural Research, Education and Extension Organization (AREEO) Karaj Iran
6 shared publications - Maryam Dadmanesh
Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran
5 shared publications - Mohammad Gholami
Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran
4 shared publications Mohammad Momeni
A Immunology of Infectious Diseases Research Center , Rafsanjan University of Medical Sciences , Rafsanjan , Iran
4 shared publications- Mohammad Kazemi Arababadi
Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
3 shared publications
Latest Publications
- Open Access
- 16 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0330865
Comparison the impact of IFN-β alone or in combination with vitamin D on critical pathways involved in AML progression
Background: Acute myeloid leukemia (AML) is a malignant disorder characterized by the accumulation of immature myeloid cells which can be developed and exacerbated through inflammation. Interferon-β (IFN-β) and vitamin D (Vit D) are known for their immunomodulatory and anti-proliferative effects. Key molecules like IL-1β, Gal-9, β-catenin, and NF-κB play important roles in AML progression. This study examines the effects of IFN-β alone and in combination with Vit D on U937 cell proliferation and the regulation of these key molecules. Methods: Cell counting kit-8 (CCK-8) was applied to assess the effect of IFN-β and Vit D on U937 cells proliferation. Real-time PCR was carried out to evaluate the impact of IFN-β and Vit D on IL-1β, IL-10, Gal-9, β-catenin, and NF-κB genes. ELISA was performed to estimate the protein levels of IL-1β and IL-10. Western-blotting was applied to evaluate the NF-κB signaling pathway. Results: The proliferation of U937 cells reduced significantly in the presence of IFN-β, while it did not show a remarkable change following treatment with Vit D. IL-1β gene expression was reduced following either IFN-β or Vit D treatment, while IL-10 gene expression underwent a gentl increase following treatment with IFN-β, which was in contrast to Vit D treatment. IFN-β in contrast to Vit D decreased Gal-9 gene expression. β-catenin gene expression increased after IFN-β or Vit D treatment. NF-κB gene expression reduced following either IFN-β or Vit D treatment, except for the highest concentration of Vit D. At protein level, IFN-β and Vit D treatment leads to a reduction of both IL-1β and IL-10 as well as p-NF-κB. Conclusion: Our findings suggest that IFN-β effectively inhibits U937 cell proliferation and modulates key inflammatory and immune-related molecules involved in AML pathogenesis. These results highlight IFN-β as a promising agent for targeting critical pathways in AML and suggest a modulatory, but less potent role for Vit D.
- 16 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0330865
Open AccessComparison the impact of IFN-β alone or in combination with vitamin D on critical pathways involved in AML progression
Background: Acute myeloid leukemia (AML) is a malignant disorder characterized by the accumulation of immature myeloid cells which can be developed and exacerbated through inflammation. Interferon-β (IFN-β) and vitamin D (Vit D) are known for their immunomodulatory and anti-proliferative effects. Key molecules like IL-1β, Gal-9, β-catenin, and NF-κB play important roles in AML progression. This study examines the effects of IFN-β alone and in combination with Vit D on U937 cell proliferation and the regulation of these key molecules. Methods: Cell counting kit-8 (CCK-8) was applied to assess the effect of IFN-β and Vit D on U937 cells proliferation. Real-time PCR was carried out to evaluate the impact of IFN-β and Vit D on IL-1β, IL-10, Gal-9, β-catenin, and NF-κB genes. ELISA was performed to estimate the protein levels of IL-1β and IL-10. Western-blotting was applied to evaluate the NF-κB signaling pathway. Results: The proliferation of U937 cells reduced significantly in the presence of IFN-β, while it did not show a remarkable change following treatment with Vit D. IL-1β gene expression was reduced following either IFN-β or Vit D treatment, while IL-10 gene expression underwent a gentl increase following treatment with IFN-β, which was in contrast to Vit D treatment. IFN-β in contrast to Vit D decreased Gal-9 gene expression. β-catenin gene expression increased after IFN-β or Vit D treatment. NF-κB gene expression reduced following either IFN-β or Vit D treatment, except for the highest concentration of Vit D. At protein level, IFN-β and Vit D treatment leads to a reduction of both IL-1β and IL-10 as well as p-NF-κB. Conclusion: Our findings suggest that IFN-β effectively inhibits U937 cell proliferation and modulates key inflammatory and immune-related molecules involved in AML pathogenesis. These results highlight IFN-β as a promising agent for targeting critical pathways in AML and suggest a modulatory, but less potent role for Vit D.
- Open Access
- 7 January 2024
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 22 (6) , 561-574
Mesenchymal Stem Cell-derived Exosome: An Interesting Nanocarrier to Improve Allergen-specific Intranasal Immunotherapy
Increasing the efficacy of allergen-specific intranasal immunotherapy (INIT) has recently been the main goal of several studies to establish this route as a safe delivery method through mucosal pathways. In this case, the present study evaluated the potential of INIT using ovalbumin (OVA)-loaded mesenchymal stromal/stem cell (MSC)-derived exosomes (Exo-OVA) in an allergic asthma mouse model. Together with control groups, sensitized Balb/c mice underwent intranasal immunotherapy with Exo-OVA (10 μg OVA per dose) for three consecutive weeks. Serum-specific immunoglobulin E (IgE) levels, transforming growth factor-beta (TGF-β), interleukin (IL)-4, and interferon-gamma (IFN-γ) production by cultured spleen cells, lung histopathologic analysis, and nasopharyngeal lavage fluid cellular examinations were then conducted. The results showed that INIT using Exo-OVA significantly increased IFN-γ and TGF-β secretion, while allergen-specific IgE and IL-4 production were dramatically decreased compared to the control group receiving phosphate-buffered saline. In addition, the eosinophil and total cell counts in the nasopharyngeal lavage fluid were reduced, and inflammatory conditions and cell accumulation in lung tissue were ameliorated. In conclusion, the Exo-OVA improved the INIT efficacy compared to free OVA. Therefore, this formulation could be introduced as an effective approach for immunomodulatory purposes with a shorter treatment duration and reduced side effects.
- 7 January 2024
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 22 (6) , 561-574
Open AccessMesenchymal Stem Cell-derived Exosome: An Interesting Nanocarrier to Improve Allergen-specific Intranasal Immunotherapy
Increasing the efficacy of allergen-specific intranasal immunotherapy (INIT) has recently been the main goal of several studies to establish this route as a safe delivery method through mucosal pathways. In this case, the present study evaluated the potential of INIT using ovalbumin (OVA)-loaded mesenchymal stromal/stem cell (MSC)-derived exosomes (Exo-OVA) in an allergic asthma mouse model. Together with control groups, sensitized Balb/c mice underwent intranasal immunotherapy with Exo-OVA (10 μg OVA per dose) for three consecutive weeks. Serum-specific immunoglobulin E (IgE) levels, transforming growth factor-beta (TGF-β), interleukin (IL)-4, and interferon-gamma (IFN-γ) production by cultured spleen cells, lung histopathologic analysis, and nasopharyngeal lavage fluid cellular examinations were then conducted. The results showed that INIT using Exo-OVA significantly increased IFN-γ and TGF-β secretion, while allergen-specific IgE and IL-4 production were dramatically decreased compared to the control group receiving phosphate-buffered saline. In addition, the eosinophil and total cell counts in the nasopharyngeal lavage fluid were reduced, and inflammatory conditions and cell accumulation in lung tissue were ameliorated. In conclusion, the Exo-OVA improved the INIT efficacy compared to free OVA. Therefore, this formulation could be introduced as an effective approach for immunomodulatory purposes with a shorter treatment duration and reduced side effects.
- 2 February 2023
- Published by Elsevier in Gene Reports
- Vol. 31, 101747
Evaluation of Tcell exhaustion based on the expression of EOMES, Tbet and co-inhibitory receptors in severe and non-severe covid-19 patients
- 2 February 2023
- Published by Elsevier in Gene Reports
- Vol. 31, 101747
Evaluation of Tcell exhaustion based on the expression of EOMES, Tbet and co-inhibitory receptors in severe and non-severe covid-19 patients
- 31 December 2022
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 21 (6) , 677-686
β-D-mannuronic Acid (M2000) and Inflammatory Cytokines in COVID-19; An in vitro Study
Coronavirus disease of 2019 (COVID-19) can be complicated by acute respiratory distress syndrome (ARDS) and may be associated with cytokine storm and multiorgan failure. Anti-inflammatory agents, such as systemic corticosteroids, monoclonal antibodies, and nonsteroidal anti-inflammatory drugs (NSAIDs) can be used for this purpose. In this study, we evaluated the immunomodulatory effect of mannuronic acid (M2000), which is a novel NSAID, on COVID-19-related cytokine storms. This study was conducted in vitro on blood samples of 30 COVID-19 patients who presented with ARDS to a referral center. Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples and incubated with phorbol myristate acetate for 24 hours. M2000 was administered with the dosages of 25 µg/well and 50 µg/well after 4 hours of incubation at 37°C. The quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to assess mRNA gene expression. Enzyme-linked immunosorbent assay (ELISA) was performed to evaluate the supernatant PBMC levels of interleukin (IL)-6, IL-17, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ. Both mRNA expression and the supernatant PBMC levels of IL-17, TNF-α, IL‑6, and IFN‑γ were decreased in PBMCs of COVID-19 patients treated with M2000 compared with the control group. For the first time, it was observed that M2000 could be effective in alleviating the inflammatory cascade of COVID-19 patients based on an in vitro model. After further studies in vitro and in animal models, M2000 could be considered a novel NSAID drug in COVID-19 patients.
- 31 December 2022
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 21 (6) , 677-686
β-D-mannuronic Acid (M2000) and Inflammatory Cytokines in COVID-19; An in vitro Study
Coronavirus disease of 2019 (COVID-19) can be complicated by acute respiratory distress syndrome (ARDS) and may be associated with cytokine storm and multiorgan failure. Anti-inflammatory agents, such as systemic corticosteroids, monoclonal antibodies, and nonsteroidal anti-inflammatory drugs (NSAIDs) can be used for this purpose. In this study, we evaluated the immunomodulatory effect of mannuronic acid (M2000), which is a novel NSAID, on COVID-19-related cytokine storms. This study was conducted in vitro on blood samples of 30 COVID-19 patients who presented with ARDS to a referral center. Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples and incubated with phorbol myristate acetate for 24 hours. M2000 was administered with the dosages of 25 µg/well and 50 µg/well after 4 hours of incubation at 37°C. The quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to assess mRNA gene expression. Enzyme-linked immunosorbent assay (ELISA) was performed to evaluate the supernatant PBMC levels of interleukin (IL)-6, IL-17, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ. Both mRNA expression and the supernatant PBMC levels of IL-17, TNF-α, IL‑6, and IFN‑γ were decreased in PBMCs of COVID-19 patients treated with M2000 compared with the control group. For the first time, it was observed that M2000 could be effective in alleviating the inflammatory cascade of COVID-19 patients based on an in vitro model. After further studies in vitro and in animal models, M2000 could be considered a novel NSAID drug in COVID-19 patients.
- 1 September 2020
- Published by Elsevier in Microbial Pathogenesis
- Vol. 146, 104221
HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform
- 1 September 2020
- Published by Elsevier in Microbial Pathogenesis
- Vol. 146, 104221
HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform
- 13 May 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 235 (12) , 9457-9463
STAT3 inhibition reduced PD‐L1 expression and enhanced antitumor immune responses
Colon cancer is one the most common diagnosed cancers in America and Europe. Signal transducer and activator of transcription 3 (STAT3) in colon cancer is associated with proliferation of the tumor cells and suppression of immune responses. STAT3 activation upregulates the transcription of many suppressor genes, including programmed death‐ligand 1 (PD‐L1). This study was aimed to investigate the effect of STAT3 inhibition in a colon cancer cell line, HCT‐15, and particularly in presence of samples obtained from the patients suffering from colon cancer. In this project, the expression of PD‐L1 and apoptosis‐related proteins were assessed following STAT3 inhibition, using FLLL32, in HCT‐15 cells. To evaluate the effects of STAT3 inhibition on immune response, lymphocytes from 20 men with Stage III colon cancer and 20 healthy donors were cocultured with HCT‐15 cells in presence or absence of STAT3 inhibitor. Then, T regulatory (T‐reg) cell evaluation and intracellular cytokine staining (ICS) were performed using flowcytometry to assess the T‐reg and T helper (Th) subset cytokines following STAT3 inhibition. STAT3 inhibition suppressed PD‐L1 expression and induced apoptosis in HCT‐15 cells. The population of T‐reg cells in patients with colon cancer significantly decreased after treatment with STAT3 inhibitor. ICS revealed that STAT3 inhibition promotes Th1 protective immune responses. These findings suggest that STAT3 inhibition through either induction of apoptosis in the colon cancer cells and/or activation of efficient immune responses can lead to overcome cancer‐induced immune tolerance.
- 13 May 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 235 (12) , 9457-9463
STAT3 inhibition reduced PD‐L1 expression and enhanced antitumor immune responses
Colon cancer is one the most common diagnosed cancers in America and Europe. Signal transducer and activator of transcription 3 (STAT3) in colon cancer is associated with proliferation of the tumor cells and suppression of immune responses. STAT3 activation upregulates the transcription of many suppressor genes, including programmed death‐ligand 1 (PD‐L1). This study was aimed to investigate the effect of STAT3 inhibition in a colon cancer cell line, HCT‐15, and particularly in presence of samples obtained from the patients suffering from colon cancer. In this project, the expression of PD‐L1 and apoptosis‐related proteins were assessed following STAT3 inhibition, using FLLL32, in HCT‐15 cells. To evaluate the effects of STAT3 inhibition on immune response, lymphocytes from 20 men with Stage III colon cancer and 20 healthy donors were cocultured with HCT‐15 cells in presence or absence of STAT3 inhibitor. Then, T regulatory (T‐reg) cell evaluation and intracellular cytokine staining (ICS) were performed using flowcytometry to assess the T‐reg and T helper (Th) subset cytokines following STAT3 inhibition. STAT3 inhibition suppressed PD‐L1 expression and induced apoptosis in HCT‐15 cells. The population of T‐reg cells in patients with colon cancer significantly decreased after treatment with STAT3 inhibitor. ICS revealed that STAT3 inhibition promotes Th1 protective immune responses. These findings suggest that STAT3 inhibition through either induction of apoptosis in the colon cancer cells and/or activation of efficient immune responses can lead to overcome cancer‐induced immune tolerance.
- Open Access
- 1 January 2020
- Published by Polaris in Archives Of Pharmacy Practice
- Vol. 11 (3) , 115-121
Study on the Effect of Ethanol Ginger Extract on Cell Viability And p53 Level in Breast and Pancreatic Cancer
Cancer is a widespread disease in which regulatory mechanisms of cell growth and proliferation has led into failure and results in continuous cell reproduction. Today, breast and pancreatic cancers are two common and lethal diseases. In recent years anti-cancer effects of natural products like Ginger and its bioactive compounds has taken into consideration. In this study effect of ginger treatment was evaluated on viability and the p53 level of Panc-1 and MCF-7 Cell line. At first Cancerous and
- 1 January 2020
- Published by Polaris in Archives Of Pharmacy Practice
- Vol. 11 (3) , 115-121
Open AccessStudy on the Effect of Ethanol Ginger Extract on Cell Viability And p53 Level in Breast and Pancreatic Cancer
Cancer is a widespread disease in which regulatory mechanisms of cell growth and proliferation has led into failure and results in continuous cell reproduction. Today, breast and pancreatic cancers are two common and lethal diseases. In recent years anti-cancer effects of natural products like Ginger and its bioactive compounds has taken into consideration. In this study effect of ginger treatment was evaluated on viability and the p53 level of Panc-1 and MCF-7 Cell line. At first Cancerous and
- 1 December 2019
- Published by Elsevier in Immunology Letters
- Vol. 216, 106-113
PTPN22 1858 C/T polymorphism is associated with alteration of cytokine profiles as a potential pathogenic mechanism in rheumatoid arthritis
- 1 December 2019
- Published by Elsevier in Immunology Letters
- Vol. 216, 106-113
PTPN22 1858 C/T polymorphism is associated with alteration of cytokine profiles as a potential pathogenic mechanism in rheumatoid arthritis
- 6 August 2019
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 29 (1) , 115-125
In silico molecular modeling and docking studies on the Leishmania mitochondrial iron transporter-1 (LMIT1)
- 6 August 2019
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 29 (1) , 115-125
In silico molecular modeling and docking studies on the Leishmania mitochondrial iron transporter-1 (LMIT1)
- Open Access
- 20 May 2019
- Published by CMV Verlag in Iranian Biomedical Journal
- Vol. 23 (6) , 388-394
Antitumor Effects of HPV DNA Vaccine Adjuvanted with Beclin-1 as an Autophagy Inducer in a Mice Model
Background: There is a growing interest in development of an effective adjuvant system for improving DNA vaccines. Recent findings have confirmed an important role for autophagy in both innate and adaptive immunity. The current study was undertaken to determine the efficacy of autophagy induction with Beclin-1, as a novel adjuvant system, in ...
- 20 May 2019
- Published by CMV Verlag in Iranian Biomedical Journal
- Vol. 23 (6) , 388-394
Open AccessAntitumor Effects of HPV DNA Vaccine Adjuvanted with Beclin-1 as an Autophagy Inducer in a Mice Model
Background: There is a growing interest in development of an effective adjuvant system for improving DNA vaccines. Recent findings have confirmed an important role for autophagy in both innate and adaptive immunity. The current study was undertaken to determine the efficacy of autophagy induction with Beclin-1, as a novel adjuvant system, in ...